Compare OSCR & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OSCR | BIO |
|---|---|---|
| Founded | 2012 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Accident &Health Insurance | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0B | 10.1B |
| IPO Year | 2021 | 1994 |
| Metric | OSCR | BIO |
|---|---|---|
| Price | $29.93 | $381.95 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 4 |
| Target Price | $16.88 | ★ $339.75 |
| AVG Volume (30 Days) | ★ 4.9M | 243.5K |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 142.61 |
| EPS | ★ 3.16 | N/A |
| Revenue | ★ $11,701,427,000.00 | $2,583,200,000.00 |
| Revenue This Year | $63.89 | $2.74 |
| Revenue Next Year | $5.30 | $3.20 |
| P/E Ratio | $9.14 | ★ N/A |
| Revenue Growth | ★ 27.50 | 0.65 |
| 52 Week Low | $10.69 | $236.73 |
| 52 Week High | $34.48 | $396.23 |
| Indicator | OSCR | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 43.26 | 59.15 |
| Support Level | $28.13 | $364.41 |
| Resistance Level | $33.08 | $396.23 |
| Average True Range (ATR) | 1.93 | 9.28 |
| MACD | -0.40 | -1.15 |
| Stochastic Oscillator | 24.35 | 71.71 |
Oscar Health Inc is a healthcare technology company built around a full stack technology platform and a relentless focus on serving its members. It offers Individual & Family plans and health technology solutions that power the healthcare industry. Oscar operates as one segment to sell insurance to individuals, families and employees through the federal and state-run healthcare exchanges formed in conjunction with the Patient Protection and Affordable Care Act (ACA) and leverages its technology platform to provide services via its Oscar offering.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.